These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2205095)

  • 1. Acquired von Willebrand disease in multiple myeloma secondary to absorption of von Willebrand factor by plasma cells.
    Richard C; Cuadrado MA; Prieto M; Batlle J; López Fernández MF; Rodriguez Salazar ML; Bello C; Recio M; Santoro T; Gomez Casares MT
    Am J Hematol; 1990 Oct; 35(2):114-7. PubMed ID: 2205095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies of the pathophysiology of acquired von Willebrand's disease in seven patients with lymphoproliferative disorders or benign monoclonal gammopathies.
    Mannucci PM; Lombardi R; Bader R; Horellou MH; Finazzi G; Besana C; Conard J; Samama M
    Blood; 1984 Sep; 64(3):614-21. PubMed ID: 6432075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired von Willebrand disease and multiple myeloma: a case report of a breast cancer survivor.
    Jin N; Salahuddin FF; Nesbitt JA
    Blood Coagul Fibrinolysis; 2014 Dec; 25(8):890-3. PubMed ID: 24911454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DDAVP in acquired von Willebrand syndrome associated with multiple myeloma.
    Takahashi H; Nagayama R; Tanabe Y; Satoh K; Hanano M; Mito M; Shibata A
    Am J Hematol; 1986 Aug; 22(4):421-9. PubMed ID: 3088986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A probable double heterozygous type II von Willebrand's disease with increased ristocetin induced platelet aggregation.
    Kinoshita S; Yoshioka K; Kasahara M; Takamiya O
    Am J Hematol; 1992 Jul; 40(3):192-8. PubMed ID: 1609773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired von Willebrand disease associated with multiple myeloma; characterization of an inhibitor to von Willebrand factor.
    Mohri H; Tanabe J; Ohtsuka M; Yoshida M; Motomura S; Nishida S; Fujimura Y; Okubo T
    Blood Coagul Fibrinolysis; 1995 Sep; 6(6):561-6. PubMed ID: 7578899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new variant of von Willebrand's disease (type I Padua): doublet-organized plasma von Willebrand factor oligomers in the presence of all size multimers.
    Casonato A; Pontara E; Dannhäuser D; Bertomoro A; Sartori MT; Girolami A
    Haematologia (Budap); 1994; 26(2):97-109. PubMed ID: 7890268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of a bleeding tendency in severe acquired von Willebrand's disease. The role of platelet von Willebrand factor in maintaining normal hemostasis.
    Drouin J; Lillicrap DP; Izaguirre CA; Sutherland M; Windsor S; Benford K; Hoogendorn H; Giles AR
    Am J Clin Pathol; 1989 Oct; 92(4):471-8. PubMed ID: 2508465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteolytic degradation of von Willebrand factor after DDAVP administration in normal individuals.
    Batlle J; Lopez-Fernandez MF; Lopez-Borrasca A; Lopez-Berges C; Dent JA; Berkowitz SD; Ruggeri ZM; Zimmerman TS
    Blood; 1987 Jul; 70(1):173-6. PubMed ID: 3496131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Causes, etiology and diagnosis of acquired von Willebrand disease: a prospective diagnostic workup to establish the most effective therapeutic strategies.
    Sucker C; Michiels JJ; Zotz RB
    Acta Haematol; 2009; 121(2-3):177-82. PubMed ID: 19506364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idiopathic immune-mediated acquired von Willebrand's disease in a patient with angiodysplasia: demonstration of an unusual inhibitor causing a functional defect and rapid clearance of von Willebrand factor.
    Alhumood SA; Devine DV; Lawson L; Nantel SH; Carter CJ
    Am J Hematol; 1999 Feb; 60(2):151-7. PubMed ID: 9929110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired von Willebrand disease--hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin, and continuous factor concentrate infusion.
    Frank RD; Kunz D; Wirtz DC
    Am J Hematol; 2002 May; 70(1):64-71. PubMed ID: 11994985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired type II von Willebrand's disease associated with adrenal cortical carcinoma.
    Facon T; Caron C; Courtin P; Wurtz A; Deghaye M; Bauters F; Mazurier C; Goudemand J
    Br J Haematol; 1992 Apr; 80(4):488-94. PubMed ID: 1581233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired von Willebrand disease.
    van Genderen PJ; Michiels JJ
    Baillieres Clin Haematol; 1998 Jun; 11(2):319-30. PubMed ID: 10097810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired type II von Willebrand's disease: demonstration of a complexed inhibitor of the von Willebrand factor-platelet interaction and response to treatment.
    Goudemand J; Samor B; Caron C; Jude B; Gosset D; Mazurier C
    Br J Haematol; 1988 Feb; 68(2):227-33. PubMed ID: 3126793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factor VIII/von Willebrand factor concentrate therapy for ventricular assist device-associated acquired von Willebrand disease.
    Cushing M; Kawaguchi K; Friedman KD; Mark T
    Transfusion; 2012 Jul; 52(7):1535-41. PubMed ID: 22229973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: unexpected bleeding in the operating room: the role of acquired von Willebrand disease.
    Lison S; Dietrich W; Spannagl M
    Anesth Analg; 2012 Jan; 114(1):73-81. PubMed ID: 22025497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [IgA RIPA inhibitor in a case of acquired von Willebrand syndrome].
    Takai Y; Koya H; Himei S; Hayashi H
    Rinsho Ketsueki; 1989 Dec; 30(12):2183-8. PubMed ID: 2621801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.